IL154299A0 - Treatment of hepatitis c with thymosin, interferon and ribavirin - Google Patents

Treatment of hepatitis c with thymosin, interferon and ribavirin

Info

Publication number
IL154299A0
IL154299A0 IL15429901A IL15429901A IL154299A0 IL 154299 A0 IL154299 A0 IL 154299A0 IL 15429901 A IL15429901 A IL 15429901A IL 15429901 A IL15429901 A IL 15429901A IL 154299 A0 IL154299 A0 IL 154299A0
Authority
IL
Israel
Prior art keywords
hepatitis
thymosin
interferon
ribavirin
treatment
Prior art date
Application number
IL15429901A
Other languages
English (en)
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of IL154299A0 publication Critical patent/IL154299A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15429901A 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin, interferon and ribavirin IL154299A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22331700P 2000-08-07 2000-08-07
PCT/US2001/041550 WO2002011749A1 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin, interferon and ribavirin

Publications (1)

Publication Number Publication Date
IL154299A0 true IL154299A0 (en) 2003-09-17

Family

ID=22835988

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15429901A IL154299A0 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin, interferon and ribavirin

Country Status (18)

Country Link
EP (1) EP1311279B1 (de)
KR (1) KR100851861B1 (de)
CN (1) CN1446096A (de)
AT (1) ATE348628T1 (de)
AU (2) AU8353601A (de)
BR (1) BR0113115A (de)
CA (1) CA2418085A1 (de)
CY (1) CY1106388T1 (de)
DE (1) DE60125377T2 (de)
DK (1) DK1311279T3 (de)
EA (1) EA007785B1 (de)
ES (1) ES2275711T3 (de)
HK (1) HK1055689A1 (de)
IL (1) IL154299A0 (de)
MX (1) MXPA03001145A (de)
NZ (1) NZ524579A (de)
PT (1) PT1311279E (de)
WO (1) WO2002011749A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733518A1 (en) * 2008-08-06 2010-02-11 Sciclone Pharmaceuticals, Inc. Treatment or prevention of hepatitis c with immunomodulator compounds
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
RU2473341C1 (ru) * 2011-08-02 2013-01-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития) Способ профилактики вертикальной передачи вирусов гепатитов в и с у беременных с реактивацией вирусов в третьем триместре

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
KR20010052622A (ko) * 1998-06-08 2001-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
CA2354536A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy

Also Published As

Publication number Publication date
BR0113115A (pt) 2003-06-10
HK1055689A1 (en) 2004-01-21
ES2275711T3 (es) 2007-06-16
DK1311279T3 (da) 2007-02-12
EA200300222A1 (ru) 2003-08-28
EP1311279A1 (de) 2003-05-21
ATE348628T1 (de) 2007-01-15
CN1446096A (zh) 2003-10-01
KR20030034129A (ko) 2003-05-01
EP1311279B1 (de) 2006-12-20
KR100851861B1 (ko) 2008-08-13
DE60125377T2 (de) 2007-09-27
AU8353601A (en) 2002-02-18
CA2418085A1 (en) 2002-02-14
CY1106388T1 (el) 2011-10-12
NZ524579A (en) 2004-06-25
MXPA03001145A (es) 2004-08-02
EA007785B1 (ru) 2007-02-27
AU2001283536B2 (en) 2005-09-01
PT1311279E (pt) 2007-03-30
EP1311279A4 (de) 2004-08-11
WO2002011749A1 (en) 2002-02-14
DE60125377D1 (de) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
TWI317735B (en) Methods and compositions for treating hepatitis c virus
MY117781A (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
PL1658302T3 (pl) Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
AR023541A1 (es) Terapia de combinacion para vhc
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
MD990258A (en) Method of treatment of the acute viral hepatitis B
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
MD2549G2 (ro) Metodă de tratament a hepatitei virale cronice C.
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
WO2001045642A3 (en) Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease
James Ribavirin approved for hepatitis C combination treatment
WO2008021536A3 (en) Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
TW200513258A (en) Auxiliary agent for hepatitis C
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica